PT  - JOURNAL ARTICLE
AU  - NGUYEN, MINH DUNG
AU  - GOROBETS, OLENA
AU  - DJOUA, YANNICK JOEL
AU  - ROSE-DITE-MODESTINE, JOHAN
AU  - VINH-HUNG, VINCENT
AU  - VERSCHRAEGEN, CLAIRE
AU  - NGUYEN, NAM P.
TI  - End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
AID  - 10.21873/anticanres.17625
DP  - 2025 Jun 01
TA  - Anticancer Research
PG  - 2535--2538
VI  - 45
IP  - 6
4099  - http://ar.iiarjournals.org/content/45/6/2535.short
4100  - http://ar.iiarjournals.org/content/45/6/2535.full
SO  - Anticancer Res2025 Jun 01; 45
AB  - Background/Aim: Enzalutamide is a highly effective anti-androgen for the treatment of prostate cancer. Therapy can incur unbearable fatigue in elderly patients, which might require a reduced dosage. However, the value of reduced-dose treatment to improve the long-term tolerability and to decrease the risk of toxicity remains unknown.Case Report: We present the six-year clinical course of a patient treated upfront with low-dose enzalutamide (25% of the standard dose). Despite initial disease control and tolerance, the patient developed progressive frailty and signs of severe androgen deprivation near end-of-life.Conclusion: This case illustrates that while low-dose enzalutamide can provide durable disease control in elderly patients with metastatic castration-resistant prostate cancer, it does not fully prevent the late-onset toxicities associated with androgen deprivation. Personalized treatment strategies – including dose adjustment over time and consideration of intermittent therapy – may help to balance efficacy with quality of life.